Q-omics provides the consensus-scored FZD10 profile across patient tissues and cancer cell-line models. FZD10 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FZD10 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, FZD10 RNA expression shows 13,883 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UCEC, LUSC, and LIHC as cancer lineages where FZD10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FZD10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FZD10 survival associations across molecular data types. FZD10 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FZD10 RNA expression–survival associations across cancer types. High FZD10 expression shows unfavorable associations in ACC, KIRP, THCA and KIRC, but favorable associations in UCEC and GBM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FZD10 RNA expression.
This table summarizes FZD10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FZD10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FZD10 shows lower tumor expression in PRAD and higher tumor expression in LUSC, LIHC, UCEC, COAD and HNSC. The LUSC box plot shows higher FZD10 RNA expression in tumor versus normal tissue (log2 FC = +1.791, t-test p < 0.001).
This table shows molecular features associated with FZD10 in patient tissues and cancer cell lines. In patient samples, FZD10 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, FZD10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
